SITC

Society for Immunotherapy of Cancer

The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Established in 1984, SITC, a 501(c)(3) not-for-profit organization, serves scientists, clinicians, academicians, patients, patient advocates, government representatives and industry leaders from around the world. Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. Currently, SITC has more than 2,400 members who represent 22 medical specialties in 42 countries around the world.

SITC’s membership reached an all-time high in 2018, when it exceeded 2,400 members for the first time. Growing exponentially, SITC’s membership has more than doubled in the past four years. SITC’s Annual Meeting & Pre-Conference Programs is the leading destination for scientific exchange, education and networking in the cancer immunotherapy field, with growing attendee numbers each year. In the past three years, the attendee number has more than doubled. Meanwhile, SITC’s total unrestricted net assets have been on an upward trajectory since 2009, and sharply increased in the past three years, more than doubling between 2015 and 2017.